Lumendi Platforms to be Discussed in Investor’s Webcast 31 March 2021 with Panel of Clinical Experts
New EZ Glide, activated by water or saline, improves endoscopic performance of the DiLumen Endoluminal Interventional Platform (EIPTM). (Photo: Business Wire)
March 29, 2021
WESTPORT, Conn.–(BUSINESS WIRE)–Connecticut-based medical device innovator Lumendi, LLC (www.lumendi.com) has launched EZ Glide, a proprietary hydrophilic coating applied to the inner sheath of its DiLumen EIP, a double-balloon endoluminal device that aims to safely improve the navigation of the endoscope through the bowel, create a stabilizing therapeutic zone inside the colon during endoluminal interventions, and help minimize potential mucosal injury.
“The DiLumen EIP has the potential to improve or enable less invasive procedures for benign colorectal polyps, and can take the place of open or laparoscopic surgery, thereby preserving anatomy, shortening recovery and reducing healthcare costs”
EZ Glide is activated by water or saline and improves endoscopic performance of the DiLumen EIP by:
- further stabilizing the endoscope tip and nearby anatomy;
- providing gentler anatomic control to safely straighten and navigate tortuous anatomy for improved control and faster access to lesions;
- reducing the need for messy gels or oils during preparation, which further improves intraoperative visibility; and
- enabling safe and repeated access as a conduit, allowing efficient exchange of tools and tissue removal.
“The DiLumen EIP has the potential to improve or enable less invasive procedures for benign colorectal polyps, and can take the place of open or laparoscopic surgery, thereby preserving anatomy, shortening recovery and reducing healthcare costs,” said Dr. Peter Johann, CEO of Lumendi LTD, who noted that researchers at the University of Florida (Gainesville) concluded that surgery is greatly overused for benign colorectal polyps. [Surgery_Overused_for_Benign_Colorectal_Polyp].
Investor Webcast: The DiLumen platform and EZ Glide will be discussed in a webcast on March 31, 2021. A panel of three current clinical experts — Dr. Mohamed Othman, Associate Professor of Medicine (Gastroenterology & Hepatology) at Baylor College of Medicine; Dr. Emre Gorgun, Director of Endoluminal Surgery Center, Lower GI (Colorectal Surgery) at the Cleveland Clinic; and Dr. Joo Ha Hwang, Professor of Medicine (Gastroenterology & Hepatology), Stanford University Medical Center — will discuss their experiences with the platforms and their potential to improve the execution and outcomes of endoluminal surgeries in the lower and upper GI, insights into product features, clinical benefits and future applications. The event is sponsored by Lumendi and Lincoln International.
About Lumendi, LLC (Lumendi) Headquartered in Westport, Connecticut, Lumendi, LLC is a wholly owned subsidiary of Lumendi Ltd., a privately held innovative, medical device company based in Buckinghamshire, UK. Lumendi focuses on developing, marketing, and distributing surgical tools and devices that provide safe, cost-effective solutions for minimally invasive gastrointestinal interventions.
Media Contact: Deanne Eagle
Donna K. Ramer